A B S T R A C T The rate of secretion of prostacyclin (PGI2) into the circulation ofnormal man was estimated by measurement of the 2,3-dinor-6-keto-PGF,1a (D) and 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGF1a (KDD) urinary metabolites of PGI2. Subjects received 6-h intravenous infusions of vehicle alone and PGI2 at 0.1, 0.4, and 2.0 ng/kg per min in random order. The fractional elimination of the metabolites was independent ofthe rate of PGI2 infusion. 6.8 ±0.3% of the infused PGI2 appeared as D and 4.1±0.4% as KDD. The regression of infused PGI2 upon the quantities of the two metabolites excreted in excess ofcontrol values permitted estimation ofthe rate of entry of endogenous PGI2 into the circulation corresponding to a given quantity of metabolite excreted. Using the quantities excreted in the 24 h from commencement of the infusions the estimated rates were 0.08±0.02 ng/kg per min from D and 0.10±0.03 from KDD. Studies with exogenous PGI2 suggest that infusion rates of 2-4 ng/ kg per min are required to achieve the threshold for inhibition of platelet function (ex vivo) in man. Although not precluding a role for PGI2 in local plateletvessel wall interactions, the much lower estimates obtained in this study suggest that endogenous PGI2 is unlikely to act as a circulating antiplatelet agent in healthy man.
INTRODUCTION
Prostacyclin (PGI2)1 relaxes vascular smooth muscle (1) and potently inhibits platelet aggregation (2) . Unlike other prostaglandins (3), PGI2 is not extensively metabolized by the lung (4) and has been proposed as a physiologically important hormone in vivo. Both Gryglewski et al. (5) and Moncada et al. (6) The subjects received 6-h intravenous infusions of vehicle alone (glycine buffer, pH 10.5), and PGI2 at 0.1, 0.4, and 2.0 ng/kg per min in random order. Low rates of infusion were chosen to minimize the likelihood of altering metabolism secondary to changes in organ-related blood flow. Infusions were separated by 6-d intervals. Urine was collected for determination of PGI2 metabolites in two hourly aliquots during and immediately after the infusion. The subjects were permitted a light breakfast on the morning ofthe investigation. The studies commenced at 1400 h and a snack was provided at 1700 h. A collection of urine for PGI2 metabolites was obtained on a separate occasion during which the volunteers were ambulant.
Analytical methods. The rate of entry of endogenous prostacyclin into the circulation was estimated by quantification of the 2,3-dinor-6-keto-PGF,,, and the 15-keto-13,14-dihydro-2,3-dinor-6-keto PGF1,, metabolites of PGI2 in urine.
Stable isotope ratio methods were developed, using gaschromatography-mass spectrometry in the selected ion monitoring mode (11) . Briefly, the initial step was synthesis of deuterium-and tritium-labeled 6-keto-PGFI,, which subsequently was converted to the metabolites. Deuterium was incorporated into positions 10 and 8 of PGE2 by exchange with deuterium-labeled carbitol, and the 9-ketone reduced to yield deuterated PGF2a. This was derivatized to 2H3)-PGF?,.. In a similar procedure, tritium was incorporated into the 9 position by the reduction of the deuterium-labeled PGE2 by sodium borotritiide. Recovery and identification of the metabolites was monitored by addition of deuteriumand tritium-labeled metabolites of 6-keto-PGF,,, to the urine before extraction, derivatization and gas-chromatographymass spectrometry.
Statistical analysis. Significance ofthe data was evaluated by Student's t test. Owing to the inequality of variance in the metabolites excreted at different doses of PGI2, regression analysis was performed by a weighted least squares approach (12) . Two-tailed probabilities were employed throughout the analysis. All values are expressed as the mean+SEM.
RESULTS
Blood pressure and heart rate were unchanged from control values during the PGI2 infusions. There was no significant difference between the total quantities of 2,3-dinor-6-keto-PGFiat (499.9+46 ng vs. 374.9±80.2 ng; P > 0.10) and 15-keto-13,14-dihydro-2,3-dinor6-ketoPGFSc, (229.1±33 ng vs. 200.0+49 ng; P > 0. 10) excreted on the ambulant and infusion control days. The rates ofexcretion ofthe two metabolites during the collection periods on the infusion control day are illustrated in Table I . Metabolite excretion increased during the sequential 2-h collection periods within each PGI2 infusion (Fig. 1) . The fractional elimination of the metabolites was independent of the rate of PGI2 infusion. A mean 6.8% of the infused PGI2 appeared as 2,3-dinor-6-keto-PGF1, and a mean 4.1% as 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGF1a (Table II) .
Interpolation of metabolite values obtained on the control infusion day onto the linear relationship between the quantities of infused PGI2 and the amount of the metabolite excreted in excess of control values permitted calculation ofthe rate ofentry ofendogenous PGI2 into the circulation (Fig. 2 ). For these purposes, it was assumed that the linear relationship between the rate of PGI2 infused and the quantities of metabolites excreted existed for PGI2 below 0.1 kg/min. Although it would be logically expected that when the Y variable (infused PGI2) was zero the X variable (quantity of urinary metabolite excreted in excess of control values) would also be zero, the regression lines were tested against the hypothesis that the Y intercept was zero prior to forcing the lines through the origin (13) . The regressions of infused PGI2 upon both the 2,3-dinor-6-keto-PGFi,a (t = 1.46; P > 0.05) and the 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGFI, (t = 0.047; P > 0.05) yielded estimates of the Y intercept which were not significantly different from zero.
Linear equations were obtained by regression of infused PGI2 upon the 24-h quantities of the metabolites excreted in excess of control values. Insertion of the quantities of the metabolites excreted during the 6-h control infusions into these equations permitted estimation ofthe rate of entry of endogenous The excretion of the prostacyclin metabolites is expressed per milligram of creatinine excreted during the two control periods: (a) "ambulant" control, when a 24-h collection was performed while the subjects were otherwise unrestricted (b) infusion control, when the subjects received an intravenous infusion of vehicle alone (glycine buffer pH 10.5) from hours 0-6, during which they lay supine and were thereafter unrestricted.
PGI2 into the circulation. The estimated rates were 0.08+0.02 ng/kg per min from the 2,3-dinor-6-keto-PGFk, metabolite and 0.10+0.03 ng/kg per min from 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGF1,,, (Table III) .
Finally, these metabolites arise by enzymatic conversion from PGI2 or 6-keto-PGF111 (14) . The major portion of this enzymatic activity is thought to occur in the liver and kidney following the entry ofPGI2 into the circulation. However, should some conversion occur within the organ of biosynthesis the value that we have obtained may slightly overestimate the rate of PGI2 secretion into the bloodstream.
DISCUSSION
We have estimated the rate of entry of endogenous PGI2 into the bloodstream by quantification of 2 major urinary metabolites of PGI2 in man (14, 15) . Because PGI2 may have been converted in part to these metabolites prior to its entry into the circulation, the rates obtained represent maximal estimates. The mean value obtained using the 2,3-dinor-6-keto-PGF1,,: metabolite (0.08 ng/kg per min) was remarkably concordant with the estimate derived from the 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGF1,, (0.10 ng/kg per min).
Studies with exogenous PGI2 suggest that infusion rates of 2-3 ng/kg per min are required to achieve the threshold for either inhibition of platelet function ex vivo (16) or systemic hemodynamic effects in man (16, 17) . Although the threshold antiplatelet effect ofprostacyclin in vivo may be somewhat less than studies ex vivo suggest, the much lower estimates of the rate of entry ofendogenous PGI2 into the bloodstream suggest that it is unlikely to have a physiological role as a circulating hormone in man.
The suggestion that the lungs might act, not only as filters for unwanted vasoactive substances, but as generators of circulating hormones was supported by the observations of Gryglewski (5) and Moncada (6) and their colleagues. They demonstrated that exogenous PGI2 decreased superfused ex vivo tendon weight in heparinized, anesthetized rabbits and cats and that this effect was inhibited by infusion of an antiserum to a stable PGI2 analogue (5,6-dihydro-PGI2). Tendon weight gain, due to deposition of platelet aggregates (17) occurred in the absence of exogenous PGI2 and was enhanced by the additional PGI2 antibodies. This effect was more pronounced in arterial than venous blood, suggesting the pulmonary generation of a systemically active, PGI2-like substance. This proposal was further supported by the demonstration of an arterio-venous gradient of 6-keto-PGFs,l, the hydration production of PGI2, in humans undergoing cardiac catheterization (18) . However, Smith et al. (8) failed to demonstrate an effect of infusion of PGI2-binding antibodies (to 6-keto-PGF1G) on basal blood pressure in anesthetized cats even though the antiplatelet and vasodepressor response to a concomitant infusion of exogenous PGI2 could be inhibited. Steer et al. (9) PGI2 binding antibodies (to 5,6-dihydro-PGI2) to human platelet-rich plasma after either arterial or venous blood collection failed to alter platelet aggregation. Addition of these antibodies to platelet-rich plasma inhibited the effects ofexogenous PGI2 on both aggregation and platelet cyclic AMP. Whereas these investigations suggested that PGI2 was unlikely to act as a physiologically important antiplatelet circulating agent, similar studies with antibodies to 5,6-dihydro-PGI2 led Pace-Asiak and his colleagues (10) to conclude that PGI2 did not act as a systemic vasodepressor hormone in the normotensive or hypertensive rat. Considerable controversy also exists as to the concentration of6-keto-PGF1<, in human plasma. Estimates have ranged from 10-15 ng/ml using superfusion techniques (19) to 100-200 pg/ml using both radioimmunoassay (20) and gas chromatography-mass spectrometry (21) . Recently the use of gas chromatographelectron capture methods suggests that "resting" levels may be much lower (22 Total quantities of the two metabolites excreted on the "infusion" control day are expressed for the 6-h infusion period. The regression of the PGI2 infusion rate onto the quantities of the two metabolites excreted in excess of control values in the 24 h from the start of the infusion permit estimation of the rate of entry of endogenous PGI2 into the circulation for a given metabolite excretion (Fig. 2) . threshold concentration of PGI2 required (9) to inhibit aggregation in vitro of platelets obtained from human volunteers (36 pg/ml). The threshold for patients with peripheral vascular disease has been reported (24) to be much higher (1,500 pg/ml).
In conclusion, we have measured the excretion of two urinary PGI2 metabolites during the infusion of exogenous PGI2 over a 20-fold dose range to enable estimation of the rate of entry of endogenous PGI2 into the bloodstream. Our results do not preclude an important role for PGI2 in the local regulation of platelet vessel wall interaction. However they do suggest that secretion from the lungs or other organs, and subsequent systemic circulation ofPGI2 does not represent an important homeostatic mechanism in vivo.
